ReviewClinical pharmacology and therapeutics2011
Cancer pharmacogenomics.
Review in Clinical pharmacology and therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Genomic signatures of selection in drug metabolizing genes across cattle populations.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.Cancers · 2021Review
- Germline variants in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.European journal of clinical pharmacology · 2016Article
- Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).Journal of the National Cancer Institute · 2015Observational
- Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.Blood reviews · 2015Review
- Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Pharmacogenomics · 2014Article
- Genetic markers for prediction of treatment outcomes in ovarian cancer.The pharmacogenomics journal · 2014Review
- Making the genomic leap in HCT: application of second-generation sequencing to clinical advances in hematopoietic cell transplantation.European journal of human genetics : EJHG · 2014Review
- Pharmacogenomics in oncology care.Frontiers in genetics · 2014Review
- Pharmacogenomics in early-phase clinical development.Pharmacogenomics · 2013Review
- Cancer pharmacogenomics: strategies and challenges.Nature reviews. Genetics · 2013Review
- PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.Human molecular genetics · 2012Article
- Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Biomarkers in medicine · 2012Review
- GUCY2C molecular staging personalizes colorectal cancer patient management.Biomarkers in medicine · 2012Review
- Molecular prescreening to select patient population in early clinical trials.Nature reviews. Clinical oncology · 2012Review
- Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia.Frontiers in genetics · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.